본문 바로가기
KERD
논문KCI 등재

Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma

Sung-Bae Kim|Gyung-Yub Gong|Yoon-Koo Kang|Sei-Hyun Ahn|Jung-Shin Lee|Woo Kun Kim|Myung-Ju Ahn|Jin-Hee Ahn
대한암학회 (Korean Cancer Association)|2004.06|Cancer Research and Treatment|제36권 제3호|pp. 192-198

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류의학일반

초록

Abstract

PURPOSE: To determine whether COX-2 expression is associated with clinicopathological parameters, including c-erb-B2 overexpression and angiogenesis, and the disease- free survival of patients with operable breast cancer. MATERIALS AND METHODS: Paraffin-embedded tissue samples were selected from 205 patients surgically resected for breast cancer, between 1991 and 1997, and followed- up for at least 4 years. Samples were immunohistochemically stained with antibodies to COX-2, c-erb-B2 and CD34. RESULTS: COX-2 and c-erb-B2 expressions were detected in 118/205 (57.6%) and 58/205 (28.3%) patients, respectively. COX-2 expression was significantly higher in c-erb-B2 positive than c-erb-B2 negative tumors (75.9% vs. 49.7%, p-value 0.001). COX-2 expression was posi-tively correlated with microvessel count (13.3+/-8.0 vs. 6.6+/-7.0, p-value 0.050), but not with other clinicopathological characteristics, including tumor size, involved axil lary lymph nodes and estrogen or progesterone receptor status. Although COX-2 expression itself was not a prognostic marker, breast cancer patients with tumors that co-expressed both COX-2 and c-erb-B2 had a poorer 5-year disease-free survival rate than those that did not (60.2% vs. 78.3%, p-value 0.0527). CONCLUSION: Our data suggest that COX-2 expression occurs frequently in c-erb-B2 positive breast cancer, and co-expression of COX-2 and c-erb-B2 may be a useful prognostic marker in patients with operable breast cancer.(Cancer Res Treat. 2004;36:192-198)

참고문헌 (25)

  1. "Aspirin use andreduced risk of fatal colon cancer", 325, pp.1593~1596 (1991)
  2. "Expression of cyclooxygenase-2 (COX-2) in human invasivetransitional cell carcinoma (TCC) of the urinary blad-der", 59, pp.5647~5650 (1999)
  3. "Cyclooxygenase-2 expressionis up-regulated in squamous cell carcinoma of the headand neck", 59, pp.991~994 (1999)
  4. "Cyclooxygenase-2 expression in humanbreast cancer", 10, pp.503~507 (1997)
  5. "Prostaglandins and breast cancer", 2, pp.624~626 (1977)
  6. "Differential expression and regulationof cyclooxygenase-1 and -2 in two human breast cancer cellline", 15, pp.5125~5127 (1996)
  7. "Breast cancer and NSAID use:ameta-analysis", 84, pp.1188~1192 (2001)
  8. "Chemopreventionof breast cancer in rats by celecoxib,acyclooxygenase-2 inhibitor", 60, pp.2101~2103 (2000)
  9. "Expressionof cyclooxygenase-2 in human breast carcinoma:Relevanceto tumor tumor angiogenesis and expression of estrogenreceptor", 33, pp.286~295 (2001)
  10. "The contributions of cyclooxygenase-2 to tumorangiogenesis", 19, pp.19~27 (2000)
  11. "Cyclooxygenase inhibitors suppressangiogenesis and reduce tumor growth in vivo", 79, pp.1469~1477 (1999)
  12. "Correlation of aromatase andcyclooxygenase gene expression in human breast cancerspecimens", 140, pp.27~35 (1999)
  13. "Tissue microarrays for high-throughputmolecular profiling of tumor specimens", 4, pp.844~847 (1998)
  14. "Prognostic significance ofelevated cyclooxygenase-2 expression in breast cancer", 62, pp.632~635 (2002)
  15. "Tumorangiogenesis and metastasis correlation in invasive breastcarcinoma", 324, pp.1~4 (1991)
  16. "Use of chemotherapy plus amonoclonal antibody against HER2 for metastatic breastcancer that overexpresses HER2", 344, pp.783~792 (2001)
  17. "Expression ofcyclooxygenase-1 and cyclooxygenase-2 in human breastcancer", 90, pp.455~460 (1998)
  18. "Cyclooxygenase-2 expression in human breast cancersand adjacent ductal carcinoma in situ", 62, pp.1676~1681 (2002)
  19. "Elevated expression of cyclooxygenase-2 isa negative prognostic factor for disease-free survival andoverall survival in patients with breast carcinoma", 97, pp.2978~2987 (2003)
  20. "Cyclooxygenase-2 is overexpressed in HER-2", neu-positivebreast cancer.Evidence for involvement of AP-1 andPEA3, 2002, pp.77, 18649~18657
  21. "Regulation of cyclooxygenase-2 pathwayby HER2 receptor", 18, pp.305~314 (1999)
  22. "Decreased HER-2 tyrosine kinaseexpression in rectal mucosa of FAP patients followinglow-dose sulindac chemoprevention", 134, pp.201~207 (1998)
  23. "Targeting cyclooxygenase-2and HER-2", neu pathways inhibits colorectal carcinomagrowth, 2001, pp.120, 1713~1719
  24. "Enhanced antiproliferative effectfrom the combination of a COX-2 inhibitor and an EGFR", HER-2, pp.2003, 22[DOI]
  25. "Cyclooxygenase-2(COX-2)expression inhuman breast cancerscorrelations with known biologicalvariables and rationale for the use of COX-2 inhibitors", 21, pp.174~ (2002)

관련 논문AI추천

Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors김도연, 남은미, 이경은, 이순남, 임석아, Sun Hee Sung대한암학회 · Cancer Research and Treatment2005 · 제37권 제3호Cyclooxygenase-2: A Potential Target in Human CancerJong-Ho Won대한암학회 · Cancer Research and Treatment2004 · 제36권 제3호Expression of Cyclooxygenase-2 and its Relationship to p53 Accumulation in Colorectal Cancers김경종, 민영돈, 유소연, 이태범, 임승철, 최철희연세대학교의과대학 · Yonsei Medical Journal2007 · 제48권 제3호Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal CancerCharn Il Park, Chong Jai Kim, Hong-Gyun Wu, Kyubo Kim, Suk Won Park대한암학회 · Cancer Research and Treatment2004 · 제36권 제3호A Clinical Analysis of PTEN Expressions in Breast CancersChang Hyeok Ahn, Hang Ju Cho, Jeong Soo Kim, Kee Hwan Kim, Keun Woo Lim, Sang Seol Jung, Se Jeong Oh, Seock Ah Im, Woo Chan Park대한암학회 · Cancer Research and Treatment2003 · 제35권 제2호유방조직의 c-kit와 COX-2의 발현과 의의고숙경, 김은경, 이원미, 주종은대한병리학회 · Journal of Pathology and Translational Medicine2008 · 제42권 제3호

이 간행물의 다른 논문 (8건)

Cyclooxygenase-2: A Potential Target in Human CancerJong-Ho Wonpp. 161-162Lung Cancer Screening with Low-Dose Chest CT: Current IssuesMyeong Im Ahnpp. 163-166Expression of c-kit and p53 in Non-small Cell Lung Cancers조덕곤, 안명임, 조규도, 김성환, Hong Joo Cho, 유진영, Youn Ju Jeong, 김치홍, 조민섭, 송소향, 심병용, 김훈교pp. 167-172Combination of Gemcitabine and Cisplatin as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer박성규, Jong-Ho Won, Sang-Byung Bae, Chan-Kyu Kim, Dae-Sik Hong, Hee-Sook Park, Nam-Su Lee, Jae-Ho Byun, Kyu-Taeg Leepp. 173-177Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric CarcinomaGun Ick Hwang, Won Kil Pae, 손병호, 신준호, 박용래, 김흥대, 김용신, Chang Hak Yoo, 한원곤pp. 178-181
원문 보기